MEDICAMEQ

Medicamen Biotech financials

Market cap
₹438 Cr
Sector
Healthcare

What Medicamen Biotech Limited does

Medicamen Biotech Limited is a fully integrated pharmaceutical company with in-house R&D, API manufacturing and finished-dosage formulation capability, established in December 1993. It manufactures oncology therapeutics (under the Vivo Oncology brand) and other generics spanning cardiology, CNS, diabetology, anti-malarials, vitamins, antibiotics and pain management, sold across regulated and semi-regulated export markets in Latin America, Africa, Asia-Pacific and the Middle East. Its subsidiary Medicamen Life Sciences Private Limited (est. August 2022) markets a portfolio of tablets, capsules and syrups directly in the domestic Indian market.

Segments

  • Oncology formulations
  • General formulations / generics
  • Domestic marketing (India)
  • Research & Development
Manufacturing plants
3 (Bhiwadi, Rajasthan; Haridwar Unit I & Unit II, Uttarakhand)
Total manufacturing area
~2,77,000 sq. ft. across three plants (2,10,000 + 32,000 + 35,000 sq. ft.)
Countries served
35+
Product portfolio
100+ pharmaceutical offerings
Products registered
160
Products under registration/filing
250
Founded 1993Headquarters New Delhi, India Company website

Quarterly results

Q1 FY27: revenue up 11.3%, net profit up 15.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue45 45 30 43 47 +5%47 +4%61 +105%48 +11%
EBITDA5 7 -2 5 5 −3%4 −35%5 +437%4 −6%
Net profit1 3 2 2 2 +133%2 −44%4 +138%2 +16%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −7.1% 1Y

₹250₹300₹350₹400Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹347.6 on 10 Sept 2025 → ₹323.05. High ₹415.95 (25 Nov 2025), low ₹219.88 (17 Aug 2026).

Financials, as filed

Revenue grew 12.0% a year over 3 years, FY23 to FY26. Operating margin narrowed to 9.9%.

Year endingFY23FY24FY25FY26
Revenue₹141 Cr₹179 Cr₹163 Cr₹198 Cr
Operating profit₹24 Cr₹22 Cr₹14 Cr₹20 Cr
Operating margin17.0%12.4%8.5%9.9%
Interest₹3 Cr₹4 Cr₹3 Cr₹3 Cr
Depreciation₹6 Cr₹7 Cr₹7 Cr₹7 Cr
Net profit₹15 Cr₹9 Cr₹7 Cr₹10 Cr
Net margin10.5%5.3%4.0%5.0%
Cash from operations₹-6 Cr₹-7 Cr₹-8 Cr₹-33 Cr
Free cash flow₹-13 Cr₹-13 Cr₹-10 Cr₹-38 Cr
ROCE10.0%8.0%6.0%5.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹12 Cr₹12 Cr₹13 Cr₹13 Cr₹14 Cr₹14 Cr
Reserves₹121 Cr₹134 Cr₹181 Cr₹194 Cr₹262 Cr₹262 Cr
Borrowings₹19 Cr₹26 Cr₹26 Cr₹31 Cr₹39 Cr₹48 Cr
Other liabilities₹42 Cr₹53 Cr₹59 Cr₹56 Cr₹53 Cr₹49 Cr
Total liabilities₹194 Cr₹226 Cr₹279 Cr₹295 Cr₹367 Cr₹372 Cr
Fixed assets₹90 Cr₹92 Cr₹93 Cr₹92 Cr₹86 Cr₹85 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹8 Cr₹0 Cr
Other assets₹104 Cr₹133 Cr₹186 Cr₹203 Cr₹273 Cr₹287 Cr
Total assets₹194 Cr₹226 Cr₹279 Cr₹295 Cr₹367 Cr₹372 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs trimmed −0.24 pp while the public added +0.18 pp. The shareholder count grew 2% to 11,047.

Promoters
40.5%
FIIs
0.1%
DIIs
0.4%
Government
0.1%
Public
59.0%

Since Jun 2025

  • DIIs −0.24 pp
  • Public +0.18 pp
  • FIIs +0.07 pp

How it drifted, 12 quarters

Over this window promoters fell from 43.2% to 40.5% — −2.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 43.2%, FIIs 0.2%, DIIs 0.2%, Public 56.4%.Dec '23: Promoters 43.2%, FIIs 0.2%, DIIs 0.7%, Public 55.9%.Mar '24: Promoters 43.2%, FIIs 0.1%, DIIs 1.0%, Public 55.7%.Jun '24: Promoters 43.0%, FIIs 0.1%, DIIs 1.2%, Public 55.8%.Sep '24: Promoters 43.0%, FIIs 0.1%, DIIs 1.2%, Public 55.8%.Dec '24: Promoters 43.0%, FIIs 0.1%, DIIs 0.9%, Government 0.1%, Public 56.0%.Mar '25: Promoters 43.2%, FIIs 0.1%, DIIs 0.7%, Government 0.1%, Public 56.0%.Jun '25: Promoters 40.5%, DIIs 0.6%, Government 0.1%, Public 58.8%.Sep '25: Promoters 40.5%, FIIs 0.1%, DIIs 0.6%, Government 0.1%, Public 58.8%.Dec '25: Promoters 40.5%, FIIs 0.0%, DIIs 0.4%, Government 0.1%, Public 59.0%.Mar '26: Promoters 40.5%, FIIs 0.1%, Government 0.1%, Public 59.4%.Jun '26: Promoters 40.5%, FIIs 0.1%, DIIs 0.4%, Government 0.1%, Public 59.0%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Medicamen Biotech Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Shivalik Rasayan Limited 40.46%unchanged
Pharmadanica A/S 9.88%unchanged
Veralogix Holdings(Pty) Ltd 4.42%unchanged
Ginnerup Capital ApS 2.62%unchanged
Investor Education and Protection Fund (IEPF) 1.26%unchanged
Ritesh Kantilal Oswal 1.15%unchanged
Rajesh Madan 1.14%unchanged
Vijay Amichand Sanghvi 1.11%unchanged
Growel Remedies Limited 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Growth trap

To justify its price of ₹323, this stock must grow earnings at 33% every year for 7 years. Our analysis caps realistic growth at ~-15%. At that growth it is worth ₹25 — downside of 92%.

Growth the price implies
33.2% a year
for 7 years, fading to 4%
It has actually compounded at
-16.4% a year
net profit, FY23–FY26 · EPS -15.0%
The gap
0.5 pp
-92% downside if it only repeats history
Price today ₹323.05 Value at the reference growth ₹25.18

Change the assumptions yourself →

Learn to analyse Medicamen Biotech Limited

Guides on how to read this kind of business and the numbers that matter.